 |
Megan Elizabeth Euker | |
|---|---|
| Born | 1983 |
| Nationality | USA Italy |
| Alma mater | School of the Art Institute of Chicago |
| Website | meganeuker |
Megan Elizabeth Euker (born 1983) is an Italian and American artist and designer. [1]
| |
Megan Elizabeth Euker | |
|---|---|
| Born | 1983 |
| Nationality | USA Italy |
| Alma mater | School of the Art Institute of Chicago |
| Website | meganeuker |
Megan Elizabeth Euker (born 1983) is an Italian and American artist and designer. [1]
Since 2008, Euker has exhibited artwork internationally at museums and galleries (represented by Linda Warren Projects). [2] She did a solo exhibition, The Cure at The International Museum of Surgical Science (IMSS) in Chicago. [3]
She has curated three exhibitions of her students work at the IMSS, Chicago, featuring medical devices created under her mentorship. [4] Euker has also been featured at Matthew Rachman Gallery [5] The University Club of Chicago , [6] The Storefront Project, New York. [7] and other galleries and venues.
Euker's artwork has appeared on the covers of Wall Street Journal Bestselling book Flight of the Rondone, by Patrick Girondi published by Skyhorse Publishing, [8] as well as New City by Patrick Girondi published Skyhorse Publishing. [9] Her work has also appeared on the cover of The Philosophy of Sex by Raja Halwani [10] and the music albums Orphan’s Return [11] and Orphan's Final Chapter (Patrick Girondi & the Orphan's Dream).
Euker works with San Rocco Therapeutics as the Project Manager in their efforts to bring a safe and accessible gene therapy cure to patients with Sickle Cell Disease and Beta Thalassemia. [12] [13] She has taught at The School of the Art Institute of Chicago, [14] University of South Florida; and the Accademia di Belle Arti in Siracusa, Sicily. [15]
Euker was born in Baltimore, Maryland in 1983. She earned both BFA and MFA degrees from the School of the Art Institute of Chicago between 2005 and 2007. [14] She is a two-time Fulbright grant recipient to Italy. [16] [17]
Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.
Thalassemias are inherited blood disorders that result in abnormal hemoglobin. Symptoms depend on the type of thalassemia and can vary from none to severe. Often there is mild to severe anemia as thalassemia can affect the production of red blood cells and also affect how long the red blood cells live. Symptoms of anemia include feeling tired and having pale skin. Other symptoms of thalassemia include bone problems, an enlarged spleen, yellowish skin, pulmonary hypertension, and dark urine. Slow growth may occur in children. Symptoms and presentations of thalassemia can change over time. Thalassemia is also known as cooley's anemia or Mediterranean anemia.
Fetal hemoglobin, or foetal haemoglobin is the main oxygen carrier protein in the human fetus. Hemoglobin F is found in fetal red blood cells, and is involved in transporting oxygen from the mother's bloodstream to organs and tissues in the fetus. It is produced at around 6 weeks of pregnancy and the levels remain high after birth until the baby is roughly 2–4 months old. Hemoglobin F has a different composition than adult forms of hemoglobin, allowing it to bind oxygen more strongly; this in turn enables the developing fetus to retrieve oxygen from the mother's bloodstream, which occurs through the placenta found in the mother's uterus.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Beta thalassemias are a group of inherited blood disorders. They are forms of thalassemia caused by reduced or absent synthesis of the beta chains of hemoglobin that result in variable outcomes ranging from severe anemia to clinically asymptomatic individuals. Global annual incidence is estimated at one in 100,000. Beta thalassemias occur due to malfunctions in the hemoglobin subunit beta or HBB. The severity of the disease depends on the nature of the mutation.
John Francis Crowley is the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology advocacy organization. He served as the chairman and CEO of Amicus Therapeutics. He co-founded Novazyme Pharmaceuticals with William Canfield, which was later acquired by Genzyme Corporation, and founded Orexigen Therapeutics. In 2006, he was profiled in the book The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children by Geeta Anand. In 2010, Crowley released his memoir, Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy. Crowley and his family were the inspiration for the movie Extraordinary Measures starring Harrison Ford and Brendan Fraser in 2010. Crowley was named CEO of the Biotechnology Innovation Organization, the largest Biotechnology advocacy organization in the world, in 2023.
Peter Bussian is an American independent filmmaker, photographer and visual media consultant who is known mainly for his work with refugees and other international development issues. He has received awards for his photographs from the International Photography Awards (Lucies) and Interaction.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Patrick Girondi is an Italian-American singer, composer and pharmaceutical executive/patient advocate. He is the founder and CEO of San Rocco Therapeutics.
H. Lee Sweeney is an American scientist who studies muscle.
Voretigene neparvovec, sold under the brand name Luxturna, is a gene therapy medication for the treatment of Leber congenital amaurosis.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.
Michel Sadelain is an genetic engineer and cell therapist at Memorial Sloan Kettering Cancer Center, New York, New York, where he holds the Steve and Barbara Friedman Chair. He is the founding director of the Center for Cell Engineering and the head of the Gene Transfer and Gene Expression Laboratory. He is a member of the department of medicine at Memorial Hospital and of the immunology program at the Sloan Kettering Institute. He is best known for his major contributions to T cell engineering and chimeric antigen receptor (CAR) therapy, an immunotherapy based on the genetic engineering of a patient's own T cells to treat cancer.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
Victoria Gray was the first patient ever to be treated with the gene-editing tool CRISPR for sickle-cell disease.
Hemoglobin D (HbD) is a variant of hemoglobin, a protein complex that makes up red blood cells. Based on the locations of the original identification, it has been known by several names such as hemoglobin D-Los Angeles, hemoglobin D-Punjab, D-North Carolina, D-Portugal, D-Oak Ridge, and D-Chicago. Hemoglobin D-Los Angeles was the first type identified by Harvey Itano in 1951, and was subsequently discovered that hemoglobin D-Punjab is the most abundant type that is common in the Sikhs of Punjab and of Gujarat.